Table 5.

Pooled ORs and 95% CIs of gastric cancer associated with IL1B-511 and IL1B-31 polymorphisms based on dominant genetic models

Group of analysisIL1B-511 (T carriers vs C/C genotype)
IL1B-31 (C carriers vs T/T genotype)
n*PheterogeneityMethod of estimation
n*PheterogeneityMethod of estimation
Fixed–effects
Random–effects
Fixed–effects
Random–effects
OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
Total15<0.011.26 (1.13-1.40)1.21 (1.00-1.47)14<0.011.04 (0.93-1.17)1.04 (0.83-1.29)
Asians70.310.95 (0.81-1.13)0.96 (0.80-1.15)60.070.90 (0.76-1.07)0.91 (0.71-1.15)
Caucasians80.051.56 (1.35-1.80)1.49 (1.20-1.85)5<0.011.18 (1.00-1.40)1.11 (0.74-1.67)
    Quality score <530.151.06 (0.79 1.43)1.08 (0.71 1.63)20.060.88 (0.64-1.20)0.95 (0.51-1.79)
    Quality score ≥550.811.77 (1.49 2.09)1.77 (1.49 2.09)3<0.011.34 (1.09-1.63)1.22 (0.71-2.10)
    Matched20.211.76 (1.37-2.27)1.70 (1.19-2.42)20.021.65 (1.28-2.12)1.41 (0.71-2.82)
    Unmatched60.051.47 (1.22-1.76)1.42 (1.08-1.87)30.160.89 (0.71-1.12)0.92 (0.66-1.26)
    <200 subjects00
    200-400 subjects60.101.35 (1.11-1.65)1.34 (1.02-1.75)20.361.13 (0.78-1.65)1.13 (0.78-1.65)
    >400 subjects20.721.86 (1.50-2.31)1.86 (1.50-2.31)3<0.011.19 (0.99-1.44)1.09 (0.59-2.02)
    Controls type§ 160.081.40 (1.16-1.68)1.35 (1.03-1.77)20.361.13 (0.78-1.65)1.13 (0.78-1.65)
    Controls type 211
    Controls type 312<0.011.41 (1.14-1.76)1.34 (0.64-2.77)
Hispanics30.031.17 (0.83-1.65)1.52 (0.61-3.83)
    Quality score <51
    Quality score ≥520.011.25 (0.86-1.81)2.54 (0.39-16.68)
  • * Number of populations included.

  • Score based on source of cases, source of controls, histologic confirmation of gastric cancer, blind genotyping, and association assessment (Addendum 1).

  • Age and sex matched.

  • § Controls, type 1: blood donors/healthy subjects/nongastroenterology patients; type 2: gastroenterology patients; and type 3: population-/neighbor-based sample.